Average Co-Inventor Count = 4.73
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Aduro Biotech Holdings, Europe B.v. (11 from 12 patents)
2. Am-Pharma B.v. (4 from 8 patents)
3. E. R. Squibb Sons, Inc. (2 from 1,624 patents)
4. Merck Sharp + Dohme Corp. (1 from 2,405 patents)
5. Medarex Inc. (1 from 152 patents)
6. N.v. Organon (1 from 101 patents)
7. Merck Sharp + Dohme B.v. (1 from 55 patents)
8. Sairopa B.v. (0 patent)
19 patents:
1. 12168693 - Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
2. 12145992 - Method of treating IgA nephropathy by administering altered antibodies which bind human a proliferation-inducing ligand (APRIL) protein
3. 11959924 - Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
4. 11746340 - Chimeric alkaline phosphatase-like proteins
5. 11047864 - Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
6. 10961316 - Humanized antibodies which bind to human APRIL ('a proliferation-inducing ligand')
7. 10851164 - Anti-SIRPα antibodies
8. 10822597 - Chimeric alkaline phosphatase-like proteins
9. 10808030 - Anti-HCTLA-4 antibodies
10. 10570380 - Downstream processing of an alkaline phosphatase
11. 10556957 - Anti-CD27 antibodies
12. 10494436 - Anti-PD-1 antibodies
13. 10377830 - Method of treating IgA nephropathy by administering humanized APRIL-binding antibodies
14. 10155813 - Fully human antibodies to BTLA
15. 10107821 - Proliferation-inducing ligand (APRIL)-binding peptides